Abbott CMV diagnostic tie-up a step towards Astellas' 'precision medicine' vision
This article was originally published in Scrip
Executive Summary
A collaborative agreement with Abbott Molecular for the use of virus monitoring technology in a Phase III clinical trial with a candidate vaccine for cytomegalovirus (CMV) fits in well with Astellas' stated goal of pursuing "precision medicine".